<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00825487</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 621-101</org_study_id>
    <nct_id>NCT00825487</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients&#xD;
      with late-stage solid tumors or hematologic malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to explore the safety, tolerability and pharmacokinetics of ARQ 621 and&#xD;
      define a recommended phase 2 (RP2D)dose of ARQ 621.Treatment will be initiated at a dose&#xD;
      level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and&#xD;
      continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher&#xD;
      (cohort 8 and above). All cycles of therapy will consist of the patient taking ARQ 621&#xD;
      intravenously once weekly for 4 weeks. Dose escalation will proceed initially by doubling&#xD;
      (cohorts 2 and 3) and subsequently by a modified Fibonacci scheme. Dose escalations will be&#xD;
      performed using 3-6 patient cohorts. In these cohorts, if a single dose limiting toxicity&#xD;
      (DLT) is experienced among patients 1-3, the dose cohort will be expanded to six patients.&#xD;
      The maximum tolerated dose (MTD) will be defined as the dose level at which no greater than&#xD;
      1/6 patients experiences a DLT. Once an MTD is identified, up to an additional 20 patients&#xD;
      (with types of malignancy to be determined at a later date by study investigator and&#xD;
      clarified by study amendment) may be treated at this MTD of ARQ 621. If an MTD is not&#xD;
      identified in the initial 10 dosing cohorts, dose escalation will proceed in a manner to be&#xD;
      defined by subsequent amendment with the purpose of determining a RP2D of ARQ 621.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 621 administered intravenously.</measure>
    <time_frame>24 months estimated</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic profile of ARQ 621.</measure>
    <time_frame>24 months estimated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacodynamic profile (incl. biomarkers) of ARQ 621.</measure>
    <time_frame>24 months estimated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of ARQ 621.</measure>
    <time_frame>24 months estimated</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>ARQ 621 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 621</intervention_name>
    <description>Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).</description>
    <arm_group_label>ARQ 621 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent must be obtained and documented according to&#xD;
             International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the&#xD;
             local regulatory requirements, and permission to use private health information in&#xD;
             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior&#xD;
             to study-specific screening procedures&#xD;
&#xD;
          -  A histologically or cytologically confirmed metastatic solid tumor or&#xD;
             refractory/relapsed hematologic malignancy&#xD;
&#xD;
          -  Have a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Measurable disease as defined by:&#xD;
&#xD;
               -  Solid Tumors: Response Evaluation Criteria in Solid Tumors&#xD;
&#xD;
               -  Multiple Myeloma (MM): International Uniform Response Criteria, at least one of&#xD;
                  the following:&#xD;
&#xD;
                    -  Monoclonal protein in the plasma of ≥0.5 g/dL&#xD;
&#xD;
                    -  Monoclonal protein in the urine of ≥0.2 g/24 hr urine collection&#xD;
&#xD;
                    -  Serum immunoglobulin free light chain (FLC) ≥100 mg/L (10 mg/dL) and&#xD;
                       abnormal serum immunoglobulin kappa to lambda FLC ratio&#xD;
&#xD;
               -  Malignant Lymphoma (ML): International Working Group Response Criteria&#xD;
&#xD;
                    -  At least one site of disease ≥2 cm in longest diameter (a lesion ≥1 cm can&#xD;
                       be considered if PET positive)&#xD;
&#xD;
               -  Chronic Lymphocytic Leukemia (CLL): NCI Working Group Guidelines&#xD;
&#xD;
                    -  Lymphocytosis (5 x 10^9 /L) with B-cell marker (CD19, CD20,CD23) + CD5&#xD;
&#xD;
                    -  High-risk characteristics (hemoglobin &lt;10g/dL OR platelets &lt;100 x 10^9 /L)&#xD;
&#xD;
               -  Acute Myelogenous Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL): only&#xD;
                  patients with bone marrow or peripheral blast count of ≥20%&#xD;
&#xD;
               -  Acute Promyelocytic Leukemia (APML): patients must be refractory to all-trans&#xD;
                  retinoic acid (ATRA) and arsenic trioxide&#xD;
&#xD;
               -  Chronic Myelogenous Leukemia (CML): patients in blast crisis (bone marrow or&#xD;
                  peripheral blast count ≥20%) may be included if refractory to prior therapy and&#xD;
                  to any therapy the investigators deems of higher priority (for example, BCR-ABL&#xD;
                  inhibitors such as imatinib mesylate [Gleevec], nilotinib [Tasigna], or dasatinib&#xD;
                  [Sprycel])&#xD;
&#xD;
          -  ECOG performance status ≤2&#xD;
&#xD;
          -  Male or female patients of child-producing potential must agree to use contraception&#xD;
             or avoidance of pregnancy measures during the study and for 30 days after the last ARQ&#xD;
             621 dose&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
          -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of&#xD;
             normal (ULN) or ≤5.0 × ULN with metastatic liver disease&#xD;
&#xD;
          -  Hemoglobin (Hgb) ≥10 g/dL (except in cases considered related to hematologic&#xD;
             malignancy)&#xD;
&#xD;
          -  Total bilirubin ≤1.5 × ULN&#xD;
&#xD;
          -  Creatinine ≤1.5 x ULN (≤2.0 x ULN in cases considered related to multiple myeloma)&#xD;
&#xD;
          -  Absolute neutrophil count ≥1.5 x 10^9/L (except in cases considered related to&#xD;
             hematologic malignancy)&#xD;
&#xD;
          -  Platelets ≥100 x 10^9/L (except in cases considered related to hematologic malignancy)&#xD;
&#xD;
          -  Patients with hematologic malignancies who have progressed following at least two&#xD;
             prior treatment regimens&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents&#xD;
             within four weeks of the first dose&#xD;
&#xD;
               -  In cases of hematologic malignancies, 4-week recovery from prior anticancer&#xD;
                  treatment is not required, however the patient must recover from prior&#xD;
                  treatment-related non-hematological toxicities to grade 2 or less&#xD;
&#xD;
               -  When required for supportive care corticosteroids or hydroxyurea may be used&#xD;
&#xD;
          -  Surgery within four weeks prior to the first dose&#xD;
&#xD;
          -  Known untreated brain metastases or leptomeningeal disease&#xD;
&#xD;
               -  Patients with solid tumors who were treated for brain metastases and who have&#xD;
                  shown stable disease for at least 8 weeks prior to enrollment will be allowed&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Uncontrolled concurrent illness including, but not limited to ongoing or active&#xD;
             symptomatic infection requiring systemic therapy, clinically significant non-healing&#xD;
             or healing wounds, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild&#xD;
             exertion), uncontrolled infection or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          -  Patients having a history of Thrombotic thrombocytopenic purpura (TTP) or&#xD;
             Hemolytic-uremic syndrome (HUS) or HUS spectrum will be excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Translational Genomics Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2009</study_first_posted>
  <last_update_submitted>October 17, 2011</last_update_submitted>
  <last_update_submitted_qc>October 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>hematologic</keyword>
  <keyword>malignancy</keyword>
  <keyword>multiple</keyword>
  <keyword>myeloma</keyword>
  <keyword>malignant</keyword>
  <keyword>lymphoma</keyword>
  <keyword>chronic</keyword>
  <keyword>lymphocytic</keyword>
  <keyword>leukemia</keyword>
  <keyword>acute</keyword>
  <keyword>myelogenous</keyword>
  <keyword>promyelocytic</keyword>
  <keyword>dose escalation</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>tumor</keyword>
  <keyword>PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

